Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy

• Published in: Clinical therapeutics Vol. 42; no. 5; pp. 802 - 817
• Main Authors: Tichy, Eszter, Torres, Antoni, Bassetti, Matteo, Kongnakorn, Thitima, Di Virgilio, Roberto, Irani, Paurus, Charbonneau, Claudie
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2020; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - economics; Anti-Bacterial Agents - therapeutic use; Antibiotics; avibactam; Azabicyclo Compounds - economics; Azabicyclo Compounds - therapeutic use; CAZ-AVI; Ceftazidime; Ceftazidime - economics; Ceftazidime - therapeutic use; Clinical medicine; Clinical trials; Colistin; Cost analysis; Cost-Benefit Analysis; cost-effective analysis; Double-Blind Method; Drug Combinations; Drug dosages; Drug resistance; E coli; Female; Health care; Healthcare-Associated Pneumonia - drug therapy; Healthcare-Associated Pneumonia - economics; hospital-acquired pneumonia; Hospitals; Human subjects; Humans; Internal Medicine; Italy; Male; Medical Education; Meropenem; Meropenem - economics; Meropenem - therapeutic use; Middle Aged; Mortality; Nosocomial infection; Pathogens; Patients; Pneumonia; Ventilator-associated pneumonia; Ventilators; Young Adult; Italy; United States > US; ventilator-associated pneumonia; cost-effective analysis; ceftazidime; CAZ-AVI; hospital-acquired pneumonia; avibactam
• ISSN: 0149-2918; 1879-114X; 1879-114X
• DOI: 10.1016/j.clinthera.2020.03.014

Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose combination antibiotic approved in Europe and the United States for patients with hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP). The economic benefits of a new drug such as CAZ-AVI are required to be assessed against those of available comparators, from the perspective of health care providers and payers, through cost-effectiveness and cost-utility analyses. The objective of this analysis was to compare the cost-effectiveness of CAZ-AVI versus meropenem in the empirical treatment of appropriate hospitalized patients with HAP/VAP caused by gram-negative pathogens, from the perspective of publicly funded health care in Italy (third-party perspective, based on the data from the REPROVE (Ceftazidime-Avibactam Versus Meropenem In Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia) clinical study; ClinicalTrials.gov NCT01808092). A patient-level, sequential simulation model of the HAP/VAP clinical course was developed using spreadsheet software. The analysis focused on direct medical costs. The time horizon of the model selected was 5 years, with an annual discount rate of 3% on costs and quality-adjusted life-years (QALYs). Clinical inputs for treatment comparisons were mainly obtained from the REPROVE clinical study data. In addition to clinical outcomes observed in the trial, the model incorporated impact of resistance pathogens, based on data from published studies and expert opinion. Certain assumptions were made for some model parameters due to a lack of data. The analysis demonstrated that the intervention sequence (CAZ-AVI followed by colistin + high-dose meropenem) versus the comparator sequence (meropenem followed by colistin + high-dose meropenem) provided a better clinical cure rate (+13.52%), which led to a shorter hospital stay (−0.40 days per patient), and gains in the number of life-years (+0.195) and QALYs (+0.350) per patient. The intervention sequence had an estimated net incremental total cost of €1254 ($1401) per patient, and the estimated incremental cost-effectiveness ratio was €3581 ($4000) per QALY gained, well below the willingness-to-pay threshold of €30,000 ($33,507) per QALY in Italy. The model results showed that CAZ-AVI is expected to provide clinical benefits in hospitalized patients with HAP/VAP in Italy at an acceptable cost compared to meropenem.